UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01. Other Events.
On January 14, 2022, Nabriva Therapeutics plc (the “Company”) announced that it adjourned, without conducting any business, the Company’s extraordinary general meeting of shareholders (the “EGM”), on Friday, January 14, 2022 until Tuesday, January 18, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021. The record date for the EGM continues to be the close of business on November 19, 2021.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NABRIVA THERAPEUTICS PLC | ||
Date: January 14, 2022 | By: | /s/ Daniel Dolan |
Daniel Dolan | ||
Chief Financial Officer |
Cover |
Jan. 14, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 14, 2022 |
Entity File Number | 001-37558 |
Entity Registrant Name | NABRIVA THERAPEUTICS PLC |
Entity Central Index Key | 0001641640 |
Entity Tax Identification Number | 00-0000000 |
Entity Incorporation, State or Country Code | L2 |
Entity Address, Address Line One | 25-28 North Wall Quay |
Entity Address, Address Line Two | IFSC |
Entity Address, City or Town | Dublin 1 |
Entity Address, Country | IE |
Entity Address, Postal Zip Code | 00000 |
City Area Code | 610 |
Local Phone Number | 816-6640 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Ordinary Shares, nominal value $0.01 per share |
Trading Symbol | NBRV |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |